<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3156">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01888601</url>
  </required_header>
  <id_info>
    <org_study_id>TBC</org_study_id>
    <nct_id>NCT01888601</nct_id>
  </id_info>
  <brief_title>TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)</brief_title>
  <acronym>TRACERx</acronym>
  <official_title>TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the NSCLC evolutionary genomic landscape between primary and metastatic sites and
      the dynamics of intratumour heterogeneity over time combined with detailed clinical,
      histopathological and cancer phenotypic annotation for each patient, in order to
      significantly improve the outcomes of NSCLC patients (e.g. reduce their chance of recurrence
      and improve survival).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Intratumour heterogeneity</measure>
    <time_frame>Year 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>• Define the relationship between intratumour heterogeneity and clinical outcome following surgery and adjuvant therapy (including relationships between intratumour heterogeneity and clinical disease stage and histological subtypes of NSCLC).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">842</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NSCLC eligible for primary surgery</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>NSCLC eligible for primary surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue, blood, plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stage I-IIIA NSCLC eligible for primary surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed consent

          -  Patients ≥18 years of age, with early stage I-IIIA disease who are eligible for
             primary surgery (including stage IA; and stage IIIA considered unsuitable for
             chemoradiation)

          -  Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging
             necessitating surgery (e.g. diagnosis determined from frozen section in theatre)

          -  Primary surgery in keeping with NICE guidelines planned

          -  Agreement to be followed up in a specialist centre

          -  Performance status 0 or 1

        Exclusion Criteria:

          -  Any other current malignancy or malignancy diagnosed or relapsed within the past 5
             years (other than non-melanomatous skin cancer and in situ cervical cancer)

          -  Psychological condition that would preclude informed consent

          -  Adjuvant regimen other than platinum-based therapy (if a patient is deemed suitable
             for adjuvant therapy)

          -  Patients infected with blood borne viruses Hepatitis C, Hepatitis B and/or HIV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natasha Iles</last_name>
    <phone>02076799265</phone>
    <email>ctc.tracerx@ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>Select region</state>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Swanton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
